BRAF (B-raf proto-oncogene)

P1, N=160, Recruiting, SystImmune Inc. | N=120 --> 160

68Ga-NOTA-3P-TATE-RGD PET/CT is feasible for radioactive-iodine-negative DTC, providing complementary diagnostic information to 18F-FDG with enhanced detection of bone and brain metastases. The intense uptake observed in lesions with TERT-associated aggressive subtypes supports potential utility for specific disease identification.

The Pan Lung Cancer PCR Panel was highly concordant with other assays. The panel can be performed in local laboratories with a rapid turnaround time and represents an attractive alternative to next-generation sequencing for patients with lung cancer.

These co-regulated proteins highlight the integration of BRAF signaling with critical processes, such as cell cycle control, apoptosis, DNA damage response, and protein synthesis in melanoma. Our analysis suggests that targeting BRAF-interacting proteins may also modulate oncogenic signaling pathways and represent promising biomarkers for melanoma diagnosis and therapy.

FOXO1 carries both prognostic and predictive relevance in mRCC and independently predicts greater benefit from IO+TKI therapy. Integration of FOXO1 with complementary immune gene features into an RF-based model provides a promising framework for precision immunotherapy in advanced RCC.

Opportunities abound for development of targeted therapies for management of ameloblastoma. Potential candidates are inhibitors of BRAF/MEK and smoothened (SMO) gene/HH pathways, interruption of the TGF-β-Cancer-associated fibroblast axis, anti-angiogenic strategies, immune checkpoint blockade, and RANKL-directed therapy.

P1, N=9, Not yet recruiting, West China Hospital

Our study reveals a myeloid-centered regulatory network in thyroid cancer and highlights TNFSF12 as a context-dependent oncogene, offering novel insights into targeted therapy and immunotherapeutic strategies.

Stereotactic biopsy of diffuse brainstem tumors can be performed safely. Identification of targets for personalized therapy may be essential for management of these patients.

In a tumor-agnostic approach, biomarker-informed NSTT was associated with clinical benefit in 31.7% of the patients, with checkpoint inhibitors being the most common treatment. The INFINITY project demonstrates the feasibility of a large-scale precision oncology project in a community oncology setting and thus supports the implementation of precision oncology into routine clinical practice in Germany.

Initially diagnosed with BRAF V600E-mutated melanoma, he received Dabrafenib and Trametinib...Despite initial treatment with Triptorelin, Docetaxel, and Abiraterone, disease progression occurred...This case illustrates the value of precision medicine and the role of liquid biopsy in guiding immunotherapy decisions for complex oncological cases. It supports the relevance of molecular profiling in selecting effective treatments beyond standard indications.

After a median follow-up of 33.5 months, 36% of patients developed distant metastases, and 2 patients died of disease 8 and 32 months, respectively, after initial diagnosis. These findings expand the molecular diversity of DPN-like melanomas and provide valuable insights into their clinical outcomes.